Plus Therapeutics, Inc. announced on May 23, 2025, that it received a delinquency notification letter from Nasdaq on May 21, 2025. The notification indicated non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025.
This notification has no immediate effect on the listing of the company’s securities on Nasdaq. However, Nasdaq requires the company to submit a plan to regain compliance by July 21, 2025.
If the plan is accepted, Nasdaq may grant an exception of up to 180 calendar days, or until November 17, 2025, to regain compliance. Failure to resolve this deficiency could result in the delisting of the company's common stock.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.